Emisphere Technologies, Inc. announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S for the development and commercialization of oral formulations of four classes of Novo Nordisk's investigational molecules targeting major metabolic disorders, including diabetes and obesity, using Emisphere's oral Eligen® Technology. Under the original terms of the Agreement, Emisphere licensed to Novo Nordisk the exclusive right to develop potential product candidates in three molecule classes, and the non-exclusive right to develop potential product candidates in a fourth molecule class, using the Eligen® Technology. As part of the amendment to the Agreement, among other items, the non-exclusive molecule class was converted to an exclusive molecule class, and certain modifications were made related to development efforts. Emisphere will receive an immediate $7.0 million payment related to this new Amendment along with the opportunity to receive up to an additional $10 million in development milestone payments, $32.5 million in sales milestone payments, plus royalties for the newly converted molecule class. The existing oral GLP-1 agreement between Novo Nordisk and Emisphere remains intact and unchanged.